-
Sector Analysis
Obesity in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the obesity market through 2035. - In 2025, GlobalData estimated the total obesity market to be valued at $34.6 billion across the 7MM, with the US accounting for 82.6% of the market. Over the forecast period, the obesity market is anticipated to grow to a value of $118.2 billion in 2035. - There will be an increase in therapies with longer duration of action, such...
-
Sector Analysis
Dyslipidemia: Epidemiology Report and Forecast to 2035
Dyslipidemia is a medical condition characterized by abnormal lipid levels in the bloodstream, and includes the imbalance of cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C) (Pappan, Awosika and Rehman, 2024; Roland, 2026). Dyslipidemia increases the risk of cardiovascular disease (CVD), and has been associated with multiple diseases, including type 2 diabetes (T2D), neurodegenerative diseases, and cancer (Zhu et al., 2024). Dyslipidemia is classified into primary dyslipidemia and secondary dyslipidemia. Primary dyslipidemia refers to dyslipidemia caused...
-
Sector Analysis
Type 2 Diabetes (T2D): Epidemiology Forecast to 2035
Type 2 diabetes (T2D), formerly known as non-insulin dependent or adult-onset diabetes, is a chronic condition characterized by a non-autoimmune progressive loss of pancreatic beta cells, which produce insulin (Lu et al., 2024; World Health Organization [WHO], 2024). T2D accounts for over 90% of all diabetes cases, with type 1 and gestational diabetes making up the majority of the remaining cases (Goyal, Singhal and Jialal, 2023). T2D most commonly occurs in persons older than 45 years, however its prevalence in...
-
Sector Analysis
Diabetic Macular Edema in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the diabetic macular edema market through 2033. Drug sales in the DME pharmacotherapy market are expected to grow by a significant margin between 2024 and 2034, with an overall compound annual growth rate (CAGR) of 3.4% over the forecast period. In 2024, GlobalData estimated the total DME market to be valued at $4.42 billion across the 7MM, with the US accounting...
-
Sector Analysis
Overweight and Obesity: Epidemiology Report and Forecast to 2035
Why Does Overweight and Obesity Epidemiology Matter? Overweight and obesity are major health conditions associated with excess body fat, metabolic dysfunction, chronic inflammation, and comorbidities including diabetes and cardiovascular disease. Understanding the size and characteristics of these populations is essential for healthcare and life sciences companies developing products and commercial strategies. This report provides a comprehensive epidemiological assessment across the seven major markets (7MM), covering the US, France, Germany, Italy, Spain, the UK, and Japan. You can use this report...
-
Product Insights
Diabetic Foot Ulcers: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Diabetic Foot Ulcers - Global Clinical Trials Review, 2026" provides an overview of Diabetic Foot Ulcers Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Foot Ulcers. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Global Clinical Trials Review, 2026" provides an overview of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Clinical trials scenario. This report provides top line data relating to the clinical trials on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Hyperlipidemia: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Hyperlipidemia - Global Clinical Trials Review, 2026" provides an overview of Hyperlipidemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperlipidemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Hyperuricemia - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Hyperuricemia - Global Clinical Trials Review, 2026" provides an overview of Hyperuricemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperuricemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Phenylketonuria (PKU) - Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Phenylketonuria (PKU) - Global Clinical Trials Review, 2025" provides an overview of Phenylketonuria (PKU) Clinical trials scenario. This report provides top line data relating to the clinical trials on Phenylketonuria (PKU). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.